Conducted by The University of Basque Country's (UDV/EHU) nutrition and obesity group in collaboration with the United States Department of Agriculture (USDA), researchers observed in animal models that the administration of pterostilbene "reduces the build-up of body fat, which could reduce the risk of developing other diseases like diabetes."
In 2012 ChromaDex conducted human clinical trials that also demonstrated the effects of pterostilbene on weight loss.
USDA research chemist Agnes M. Rimando, a named collaborator on the Gomez-Zorita study, is one of the inventors of the USDA pterostilbene patents licensed by ChromaDex.
The new data from the Gomez-Zorita animal study is fully consistent with results achieved by ChromaDex in the Phase 2/3 clinical study of its pTeroPure pterostilbene. The study demonstrated that participants taking pTeroPure at 100 milligram per day lost 3.04 pounds at confidence interval of 94.45% (p=0.055). Although statistical significance is based at a 95% confidence interval, the data trended toward significance. The study also showed statistically significant results for pterostilbene's ability to lower blood pressure without any serious adverse side effects.
For more information: www.chromadex.com